SEC Filings


Form 424B3
Raptor Pharmaceutical Corp filed this Form 424B3 on 07/15/10
Document Outline
Entire Document (2042.1 KB)
Subdocument 1 - 424B3 - RAPTOR S-1 PRO SUPP FOR 10-Q 053110
Page 1 - Prospectus Supplement dated July 15, 2010 Prospectus Supplement Filed Pursuant to Rule 424(b)(3)
Page 2 - UNITED STATES
Page 3 - RAPTOR PHARMACEUTICAL CORP.
Page 4 - PART I – FINANCIAL INFORMATION
Page 5 - Raptor Pharmaceutical Corp.
Page 6 - N/A
Page 7 - N/A
Page 8 - RAPTOR PHARMACEUTICAL CORP.
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - Item
Page 30 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Page 31 - Future Activities
Page 32 - Development of DR Cysteamine for the Potential Treatment of Huntington’s Disease or HD
Page 33 - Tezampanel and NGX426 for the Potential Treatment of Migraine and Pain
Page 34 - HepTide
Page 35 - Proceedings of the National Academy of Sciences
Page 36 - Purchase of DR Cysteamine
Page 37 - Fair Value of Financial Instruments
Page 38 - Research and Development
Page 39 - Equity-Based Payments to Non-Employees
Page 40 - Research and Development
Page 41 - Current Status of Major Programs
Page 42 - Liquidity and Capital Resources
Page 43 - N/A
Page 44 - General and Administrative
Page 45 - •
Page 46 - N/A
Page 47 - Off-Balance Sheet Arrangements
Page 48 - Derivatives and Hedging,
Page 49 - Fair Value Measurements and Disclosures (Topic 820): Improving Disclosures about Fair Value Measurem
Page 50 - Changes in Internal Control Over Financial Reporting
Page 51 - •
Page 52 - Even if we are able to develop our drug product candidates, we may not be able to receive regulatory
Page 53 - If we fail to compete successfully with respect to acquisitions, joint venture and other collaborati
Page 54 - •
Page 55 - If we fail to obtain or maintain orphan drug exclusivity for some of our drug product candidates, ou
Page 56 - Companies and universities that have licensed product candidates to us for research, clinical develo
Page 57 - Our success depends on our ability to manage our growth.
Page 58 - We may be required to suspend, repeat or terminate our clinical trials if they do not meet regulator
Page 59 - We may not complete our clinical trials in the time expected, which could delay or prevent the comme
Page 60 - •
Page 61 - N/A
Page 62 - Because we do not intend to pay any cash dividends on our common stock, investors will benefit from
Page 63 - •
Page 64 - We can issue shares of preferred stock that may adversely affect the rights of a stockholder of our
Page 65 - Issuance Date
Page 66 - Item 6. Exhibits
Page 67 - SIGNATURES
Page 68 - Exhibit Index
Page 69 - N/A